MétaCan
Menu
Back to cohort
Record W4384009290 · doi:10.1055/s-0043-1769867

TROP-2 expression in vulval carcinoma – as a possible target for the treatment approach with antibody drug conjugates (ADC)

2023· article· en· W4384009290 on OpenAlexaff
Anne Kathrin Höhn, M. Forberger, Gesine Grit Ruth Hiller, Emily F. Thompson, C. Blake Gilks, Michael Höckel, Naveena Singh, Christine Brambs, Lars‐Christian Horn

Bibliographic record

VenueGeburtshilfe und Frauenheilkunde · 2023
Typearticle
Languageen
FieldMedicine
TopicHER2/EGFR in Cancer Research
Canadian institutionsVancouver General HospitalUniversity of British Columbia
Fundersnot available
KeywordsAntibodyAntibody-drug conjugateCancer researchCervical carcinomaAntigenMedicineDrugCarcinomaCancerPathologyImmunologyInternal medicineCervical cancerMonoclonal antibodyPharmacology

Abstract

fetched live from OpenAlex

Question/Background The Trophoblast Cell Surface Antigen 2 (TROP-2) is associated with invasiveness and tumor progression in several malignancies. Strong TROP-2-expression is associated with poor prognosis in cervical carcinoma. Recently, TROP-2 was identified as a target protein for treatment of solid tumors using antibody-drug conjugates (ADC). There are no details about the expression profiles of TROP-2 in vulval cancer (VCX). Methods 55 cases of squamous cell carcinomas oft he vulva were immunohistochemically analysed for TROP-2 expression using a H-score. The staining intensity (SI) was score das negative (0), weak (1), moderate (2) and strong (3). The percentage of positive stained tumor cells was calculated as 0 (complete negative staining of tumor cells), 1 (1-10% positive stained tumor cells), 2 (11-50%) and 3 (51-100%). Overall staining results were calculated by SI x percentage staining score as follows: negative (core 0), + (scores 1;2;3), ++ (scores 4-6) and +++ (score 7-9) as previously described. Overall staining scores were compared to the molecular subtypes of vulval carcinoma, defining p16+ve/p53wt, p16-ve/p53mut and p16-ve/p53wt VCX. Staining evaluation of TROP-2 was blinded to the molecular subtype. Results All 55 cases were immunohistochemically positive for TROP2. 7 cases (13%) showed weak reactivity (+), 31 cases (56%) represented moderate reactivity (++) and 17 cases (31%) strong positivity (+++). There were no significant differences within the median h-score values when the different molecular subtypes of vulvar cancer were compared (9 in p16+ve/p53wt versus 6 in p16-ve/p53mut versus 4 in p16-ve/p53wt ; p=0.079). Conclusion It has been shown that the antibody drug conjugate (ADC) topoisomerase-1-inhibitor irinotecan, coupled via a linker to a humanised IgG-1ntibody hRS7 binding to TROP-2 (i.e. sacitumzumab) represents an effective treatment approach to several carcinoma types. Virtually all examined VCX showed at least weak staining for TROP-2 within the tumor cells. So, TROP-2 may represent a potential target for ADC in vulval cancer. There are no differences of TROP-2 expression within the different molecular subtypes of VCX. Publication History Article published online: 21 June 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.367
Teacher spread0.326 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueGeburtshilfe und FrauenheilkundeSame topicHER2/EGFR in Cancer ResearchFrench-language works237,207